United States· US:0078-1196_e187165a-eb84-4ee5-98b8-d4e777ec7b4a
SCEMBLIX
A asciminib product containing asciminib hydrochloride, registered in United States by Novartis Pharmaceuticals Corporation. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Asciminib is registered in 16 of 19 countries.
Countries holding a registration under ATC L01EA06 (asciminib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Asciminib · ATC L01EA06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of asciminib costs, country by country.
Normalised to the WHO defined daily dose (80 mg), the median price runs from $0.27 in France to $162.23 in Switzerland — a ×606 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Asciminib · price per daily dose (80 mg)
USD · FX 28 Sept 2026
- CH Switzerland$162.23
- FR France$0.27
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ASCIMINIB HYDROCHLORIDE
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- L01EA06
- ATC class
- Asciminib
- Defined daily dose
- 80 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11007811962060 TABLET, FILM COATED in 1 BOTTLE (0078-1196-20)
- ndc110078-1196-20
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Asciminib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSCEMBLIXNovartis Europharm Limited, Dublin
- SwitzerlandScemblix 100 mg, FilmtablettenNovartis Pharma Schweiz AG
- SpainSCEMBLIX 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandScemblixNovartis Europharm Limited
- IrelandScemblix 100 mg film-coated tabletsNovartis Europharm Limited
- IcelandScemblixNovartis Europharm Limited*
- NetherlandsScemblix 100 mg, filmomhulde tabletNovartis Europharm Limited
- BelgiumScemblix 100 mgNovartis Europharm
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Scemblix
- Liechtenstein · Scemblix
- Norway · Scemblix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcdaa716-24f9-46f1-a4b1-02c24c71b05f GET /v1/drugs/bcdaa716-24f9-46f1-a4b1-02c24c71b05f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "ASCIMINIB HYDROCHLORIDE",
"productndc": "0078-1196",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA215358",
"marketing_category": "NDA"
}See everything about asciminib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.